SNDX
Syndax Pharmaceuticals, Inc. (SNDX) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental catalysts or controversies were reported this month.
The company remains a biotech with limited direct environmental footprint, so ESG environmental exposure is primarily indirect through operations and supply chain.
Social
No material social news or workforce/customer developments were reported this month.
Social risk remains centered on access, pricing, and patient outcomes typical of a commercial-stage biotech.
Governance
No material governance events, board changes, or capital actions were reported this month.
Governance remains a watch item given continued losses and elevated leverage metrics, but no new event changed the profile.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Syndax Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.